
Opinion|Videos|December 22, 2025
Current Treatment Guidelines for Schizophrenia
Panelists discuss how evidence-based, patient-tailored guideline adherence enhances long-term schizophrenia outcomes.
Advertisement
Episodes in this series

Panelists discuss how the latest APA guidelines advocate a multimodal approach combining pharmacologic treatment with psychosocial interventions such as cognitive-behavioral therapy and supported employment.
Panelists discuss how adherence, monitoring of adverse effects, and collaborative care are emphasized as pillars of sustained stability. Clinicians are encouraged to adapt evidence-based strategies to individual patient profiles.
Panelists discuss how guideline adherence improves outcomes, but flexibility is required to tailor interventions to patients’ unique needs, comorbidities, and cultural contexts.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
2
5 August FDA Approvals Marked by Novelty, Pushback
3
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
4
Cross-Trial Vitiligo Data: What Payers Can and Can't Compare
5





